Does rosuvastatin improve lipid levels in patients with the metabolic syndrome more effectively than atorvastatin?
Herbert Schuster
Correspondence INFOGEN, Xantener Strasse 10, 10707 Berlin, Germany
Email schuster@infogen.de
This article has no abstract so we have provided the first paragraph of the full text.
The metabolic syndrome is a cluster of the most dangerous risk factors for heart attack: type 2 diabetes or prediabetes, abdominal obesity, dyslipidemia and high blood pressure. As many as 80% of the approximately 200 million adults worldwide with diabetes will die of cardiovascular disease; however, people with the metabolic syndrome are also at increased risk. They are twice as likely to die of cardiovascular disease and three times as likely to have a myocardial infarction or stroke compared with people without the metabolic syndrome.1 By building on earlier definitions proposed by the WHO and the National Cholesterol Education Program Adult Treatment Panel III guidelines, the International Diabetes Federation produced a unified, global and easy to use diagnostic tool that acknowledges visceral obesity as the central pathology of the metabolic syndrome. In addition, two other factors from the following are required: raised triglyceride levels, low HDL cholesterol, hypertension or raised fasting plasma glucose levels.2
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
